{"id":"W2006528231","doi":"10.1378/chest.13-1579","title":"Once-Daily Umeclidinium/Vilanterol 125/25 μg Therapy in COPD","year":2014,"lang":"en","type":"article","venue":"CHEST Journal","topic":"Chronic Obstructive Pulmonary Disease (COPD) Research","field":"Medicine","cited_by":155,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Medicine; Placebo; COPD; Dry-powder inhaler; Inhaler; Bronchodilator; Adverse effect; Internal medicine; Clinical endpoint; Anesthesia; Asthma; Randomized controlled trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008785023,0.0002573902,0.0004721522,0.0003090213,0.0001487223,0.00008737615,0.0003304091,0.000148676,0.001670112],"category_scores_gemma":[0.0002216444,0.0002085144,0.0002098436,0.0002976817,0.0001935351,0.0002120418,0.00007245432,0.001174543,0.0002975929],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005202429,"about_ca_system_score_gemma":0.0004602527,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000281421,"about_ca_topic_score_gemma":0.00001866404,"domain_scores_codex":[0.9975253,0.0002294399,0.0004893048,0.0003529056,0.0007110619,0.0006919841],"domain_scores_gemma":[0.9984688,0.0001623746,0.0001518894,0.0004226787,0.0001990545,0.0005952672],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002131388,0.001314393,0.7849889,0.0005036292,0.0002490743,0.001920247,0.001173587,0.00002318917,0.01779932,0.0004434765,0.0216683,0.1677844],"study_design_scores_gemma":[0.007983539,0.0005118916,0.8957697,0.0003654717,0.00003049288,0.001600769,0.000341691,0.0008535654,0.001784893,0.0007982866,0.08970346,0.0002562626],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9746476,0.00252605,0.0002491108,0.003819861,0.0004711523,0.0003882286,0.000008916996,0.00004494398,0.01784413],"genre_scores_gemma":[0.9944311,0.00105374,0.0003495404,0.0008551042,0.001433109,0.00001894175,0.0000124167,0.00005581476,0.001790188],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1675282,"threshold_uncertainty_score":0.9992425,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03055733209277989,"score_gpt":0.3138151470602951,"score_spread":0.2832578149675152,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}